Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

References

• Abshagen U, Spörl-Radun S, Marinow J. 1980. Steady-state kinetics of bezafibrate and clofibrate in health female volunteers. Eur J Clin Pharmacol 17:305–308.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Faulds D. 1997. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 54:615–633.
   Google Scholar
• Alsheikh-Ali AA, Kuvin JT, Karas RH. 2004. Risk of adverse events with fibrates. Am J Cardiol 94:935–938.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ. 2000. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Chin Pharmacol Ther 68:122–129.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Chin Pharmacol Ther 72:685–691.
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Murphy G, Burks J, Zhao J, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hargford A, Vega JM, Paolini JF. 2004. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Chin Pharmacol 44:1054–1062.
   Google Scholar
• Chen Z-A, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. 2003. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ACC10). Mol Pharmacol 63:351–358.
   PubMed Web of Science ®Google Scholar
• Chu X-Y, Huskey Su-EW, Braun MP, Sarkadi B, Evans DC, Evers R. 2004. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156–164.
   PubMed Web of Science ®Google Scholar
• Ehrhardt M, Lindenmaier H, Burhenne, Haefeli WE, Weiss J. 2004. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 67:285–292.
   PubMed Web of Science ®Google Scholar
• Fehrenbach T, Cui Y, Faulstich H, Keppler D. 2003. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn-Schmiedeberg's Arch Pharmacol 368:415–420.
   Google Scholar
• Gugler R, Kraten JW, Jensen CJ, Klehr U, Hartlapp J. 1979. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Chin Pharmacol 15:341–347.
   PubMed Web of Science ®Google Scholar
• Hagmann W, Schubert J, Konig J, Keppler D. 2002. Reconstitution of transport-active multidrug resistance protein 2 (MRP2; ABCC2) in proteoliposomes. Biol Chem 383:1001–1009.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–146.
   PubMed Web of Science ®Google Scholar
• Hochman JH, Pudvah NT, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. 2004. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1688–1693.
   Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–37168.
   Google Scholar
• Kajosaari LI, Backman JT, Nuevonen M, Laitila J, Neuvonen PJ. 2004. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Pharmacol 58:390–396.
   Web of Science ®Google Scholar
• Kivistö KT, Zunkunft J, Hofmann U, Niemi M, Rekersbring S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. 2004. Characterisation of cerivastatin as a P-glycoprotein substrate: Studies in P-glycoprotein-expressing cell monolayers and mdrla/b knock-out mice. Naunyn-Schmiedeberg's Arch Pharmacol 370:124–130.
   Google Scholar
• Kusuhara H, Sugiyama Y. 2001. Drug-drug interactions involving the membrane transport process. In: Rodrigues AD, editor. Drug-drug interactions. Basel: Marcel Dekker. pp 123–188.
   Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. 2001. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Chin Pharmacol Ther 69:340–345.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73:538–544.
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, Coles SPC, Deeley RG, Keppler D. 1997. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807–27810.
   Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ. 2003. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25:459–471.
   PubMed Web of Science ®Google Scholar
• Miller DB, Spence JD. 1998. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155–162.
   PubMed Web of Science ®Google Scholar
• Monk JP, Todd PA. 1987. Bezafibrate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33:539–576.
   PubMed Web of Science ®Google Scholar
• Pan W-J, Gustayson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA. 2000. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40:316–323.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li Chunze, Eisenhandler R, Carlini DJ 2005. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22:71–78.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. 2002a. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280–1287.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. 2002b. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042–1051.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. 2002. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP/ABCC2). J Biol Chem 277:6497–6503.
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455–463.
   PubMed Web of Science ®Google Scholar
• Sedaghat A, Ahrens EH. 1975. Lack of effect of cholestyramine on the pharmacokinetics of Clofibrate in man. Eur J Clin Invest 5:177–185.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/0ATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616.
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CDA, Windass AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–177.
   PubMed Web of Science ®Google Scholar
• Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. 1995. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76:80A–83A.
   Google Scholar
• Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. 2001. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262–1269.
   PubMed Web of Science ®Google Scholar
• Todd PA, Ward A. 1988. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36:314–339.
   PubMed Web of Science ®Google Scholar
• Wang J-S, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. 2002. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352–1356.
   PubMed Web of Science ®Google Scholar
• Wen X, Wang J-S, Backman JT, Kivistö KT, Neuvonen PJ. 2001. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359–1361.
   PubMed Web of Science ®Google Scholar
• Wu X, Whitfield LR, Stewart BH. 2000. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209–215.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharm Dyn 4:879–885.
   PubMedGoogle Scholar
• Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y. 1996. Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Disposit 25:1123–1129.
   Web of Science ®Google Scholar
• Yamazaki M, Neway WE, Ohe T, Chen 1-Wu, Rowe JF, Hochman JH, Chiba M, Lin JH. 2001. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723–735.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. 1993. Na±-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. J Pharmacol Exp Ther 264:G36–44.
   Google Scholar